Header Logo

Connection

Kyle Amber to Autoantibodies

Back to Details
This is a "connection" page, showing publications Kyle Amber has written about Autoantibodies.
Kyle Amber
Connection Strength
3.972
Autoantibodies
  1. Subunit-Specific Reactivity of Autoantibodies Against Laminin-332 Reveals Direct Inflammatory Mechanisms on Keratinocytes. Front Immunol. 2021; 12:775412.
    View in: PubMed
    Score: 0.791
  2. Non-Desmoglein Antibodies in Patients With Pemphigus Vulgaris. Front Immunol. 2018; 9:1190.
    View in: PubMed
    Score: 0.621
  3. Is anti-BP180 IgE associated with clinical phenotype? A reply to 'Levels of anti-BP180 NC16A IgE do not correlate with severity of disease in the early stages of bullous pemphigoid'. Arch Dermatol Res. 2016 Jan; 308(1):65-6.
    View in: PubMed
    Score: 0.521
  4. C-type lectin receptor expression is a hallmark of neutrophils infiltrating the skin in epidermolysis bullosa acquisita. Front Immunol. 2023; 14:1266359.
    View in: PubMed
    Score: 0.224
  5. Insights Into the Pathogenesis of Bullous Pemphigoid: The Role of Complement-Independent Mechanisms. Front Immunol. 2022; 13:912876.
    View in: PubMed
    Score: 0.206
  6. Development of Pneumocystis pneumonia in a patient receiving both rituximab and IVIg for pemphigus vulgaris. J Dtsch Dermatol Ges. 2022 04; 20(4):520-521.
    View in: PubMed
    Score: 0.202
  7. Gene expression profiling of laminin a3-blocked keratinocytes reveals an immune-independent mechanism of blistering. Exp Dermatol. 2022 04; 31(4):615-621.
    View in: PubMed
    Score: 0.198
  8. Characterizing the proteome of bullous pemphigoid blister fluid utilizing tandem mass tag labeling coupled with LC-MS/MS. Arch Dermatol Res. 2022 Nov; 314(9):921-928.
    View in: PubMed
    Score: 0.192
  9. Autoreactive T cells in pemphigus: perpetrator and target. Ital J Dermatol Venerol. 2021 04; 156(2):124-133.
    View in: PubMed
    Score: 0.184
  10. Eosinophils in bullous pemphigoid. Panminerva Med. 2021 Sep; 63(3):368-378.
    View in: PubMed
    Score: 0.179
  11. Targeted Therapies for Autoimmune Bullous Diseases: Current Status. Drugs. 2018 Oct; 78(15):1527-1548.
    View in: PubMed
    Score: 0.159
  12. Paraneoplastic autoimmune multiorgan syndrome (PAMS): Beyond the single phenotype of paraneoplastic pemphigus. Autoimmun Rev. 2018 Oct; 17(10):1002-1010.
    View in: PubMed
    Score: 0.157
  13. Autoimmune Subepidermal Bullous Diseases of the Skin and Mucosae: Clinical Features, Diagnosis, and Management. Clin Rev Allergy Immunol. 2018 Feb; 54(1):26-51.
    View in: PubMed
    Score: 0.152
  14. Autoreactive T cells in the immune pathogenesis of pemphigus vulgaris. Exp Dermatol. 2013 Nov; 22(11):699-704.
    View in: PubMed
    Score: 0.113
  15. Synergy among non-desmoglein antibodies contributes to the immunopathology of desmoglein antibody-negative pemphigus vulgaris. J Biol Chem. 2019 03 22; 294(12):4520-4528.
    View in: PubMed
    Score: 0.041
  16. Immune response in pemphigus and beyond: progresses and emerging concepts. Semin Immunopathol. 2016 Jan; 38(1):57-74.
    View in: PubMed
    Score: 0.033
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.